ACC 2026

New data on the effects of TG lowering on plaque progression and the longer term use of plozasiran on TG levels were reported at this year’s American College of Cardiology congress in New Orleans, USA (28-30 March 2026). In addition, there were fresh insights on combined olezarsen and fibrate use in TG lowering, and the […]

Lowering TG with the apoC3 inhibitor, olezarsen, did not affect non-calcified plaque progression in patients with hypertriglyceridaemia at high risk of atherosclerosis in a one-year sub study of Essence-TIMI 73b presented at ACC.26 and published simultaneously in Circulation.1,2

Final plozasiran data from the open label extension (OLE) of the Phase 2 SHASTA trial in patients with severe hypertriglyceridaemia (HTG) and the MUIR trial in patients with moderate HTG have demonstrated robust and sustained TG lowering with a favourable safety profile, concluded Professor Christie Ballantyne and investigators.

In a second sub study from the Essence-TIMI 73b trial presented at ACC, TG reductions with olezarsen were greater in participants taking fibrates at baseline than in those who were not taking these agents. In the analysis, 309/1,349 trial patients were fibrate users, and these were younger (61 vs 64 years), more often male (65% […]

Severe and extreme hypertriglyceridaemia are associated with greater risk of both acute pancreatitis (AP) and cardiovascular events (CVE), according to an analysis of all adults with ≥1 fasting serum TG measurement in the Houston Methodist Health System (2017-2025).

Measuring TG/HDL-C ratio independently predicts 30-year total cardiovascular disease (CVD) risk, according to research reported by Professor Paul Ridker and colleagues at Brigham and Women’s Hospital, Boston, USA.